YH-GKA| CAS#N/A| glucokinase activator| MedKoo

MedKoo Cat#: 565520 | Name: YH-GKA

Description:

WARNING: This product is for research use only, not for human or veterinary use.

YH-GKA is a novel glucokinase activator, significantlt decreasing in blood glucose levels with no adverse effects on serum lipids or body weight

Chemical Structure

YH-GKA

CAS#N/A

Theoretical Analysis

MedKoo Cat#: 565520

Name: YH-GKA

CAS#: N/A

Chemical Formula: C25H24F2N2O5

Exact Mass: 470.1653

Molecular Weight: 470.47

Elemental Analysis: C, 63.82; H, 5.14; F, 8.08; N, 5.95; O, 17.00

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

YH-GKA; YH GKA; YHGKA

IUPAC/Chemical Name

(S)-6-(3-(2,6-Difluorophenethyl)-5-((1-methoxypropan-2-yl)oxy)benzamido)nicotinic acid

InChi Key

GQAYYDKEDCYYMN-HNNXBMFYSA-N

InChi Code

InChI=1S/C25H24F2N2O5/c1-15(14-33-2)34-19-11-16(6-8-20-21(26)4-3-5-22(20)27)10-18(12-19)24(30)29-23-9-7-17(13-28-23)25(31)32/h3-5,7,9-13,15H,6,8,14H2,1-2H3,(H,31,32)(H,28,29,30)/t15-/m0/s1

SMILES Code

O=C(O)C1=CN=C(NC(C2=CC(O[C@@H](C)COC)=CC(CCC3=C(F)C=CC=C3F)=C2)=O)C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 470.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Grewal AS, Sekhon BS, Lather V. Recent updates on glucokinase activators for the treatment of type 2 diabetes mellitus. Mini Rev Med Chem. 2014;14(7):585-602. Review. PubMed PMID: 25052034. 2: Oh YS, Lee YJ, Park K, Choi HH, Yoo S, Jun HS. Treatment with glucokinase activator, YH-GKA, increases cell proliferation and decreases glucotoxic apoptosis in INS-1 cells. Eur J Pharm Sci. 2014 Jan 23;51:137-45. doi: 10.1016/j.ejps.2013.09.005. Epub 2013 Sep 18. PubMed PMID: 24056026. 3: Park K. Identification of YH-GKA, a novel benzamide glucokinase activator as therapeutic candidate for type 2 diabetes mellitus. Arch Pharm Res. 2012 Dec;35(12):2029-33. doi: 10.1007/s12272-012-1201-9. Review. PubMed PMID: 23263798. 4: Park K, Lee BM, Kim YH, Han T, Yi W, Lee DH, Choi HH, Chong W, Lee CH. Discovery of a novel phenylethyl benzamide glucokinase activator for the treatment of type 2 diabetes mellitus. Bioorg Med Chem Lett. 2013 Jan 15;23(2):537-42. doi: 10.1016/j.bmcl.2012.11.018. Epub 2012 Nov 16. PubMed PMID: 23218712.